Themis Medicare Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: June 25, 2025, 8:03 pm

Market Cap	1,216 Cr.
Current Price	132
High / Low	317/115
Stock P/E	40.8
Book Value	43.7
Dividend Yield	0.38 %
ROCE	10.4 %
ROE	7.65 %
Face Value	1.00
PEG Ratio	-11.52

Stock P/E, Current Price, and Intrinsic Value Over Time

Stock P/E Current Price Intrinsic Value

View Share Price Target for Themis Medicare Ltd

Competitors of Themis Medicare Ltd

Stock Name ⇩	Market Cap ⇩	Current Price ⇩	High / Low ⇩	Stock P/E ⇩	Book Value ⇩	Dividend Yield ⇩	ROCE ⇩	ROE ⇩	Face Value ⇩
Lactose (India) Ltd	141 Cr.	100	247/84.3	27.3	41.7	0.00 %	12.9 %	9.75 %	10.0
MPS Pharmaa Ltd	5.48 Cr.	2.87	4.33/2.50		0.57	0.00 %	9.79 %	59.0 %	10.0
Gujarat Themis Biosyn Ltd	2,663 Cr.	244	390/192	50.6	20.5	0.27 %	45.0 %	33.8 %	1.00
Gujarat Terce Laboratories Ltd	41.4 Cr.	55.8	94.9/44.5		8.73	0.00 %	41.5 %	14.4 %	10.0
Gujarat Inject (Kerala) Ltd	37.7 Cr.	25.7	29.1/13.1	37.0	6.83	0.00 %	13.5 %	11.0 %	10.0
Industry Average	18,812.53 Cr	1,161.25		101.91	194.43	0.31%	16.64%	15.19%	6.18

All Competitor Stocks of Themis Medicare Ltd

Quarterly Result

Metric	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025
Sales	79.80	94.44	91.00	88.78	80.10	96.65	104.78	82.51	97.82	122.99	117.01	93.81	71.70
Expenses	65.39	74.07	69.66	73.51	69.62	74.91	92.37	74.46	88.53	93.81	99.88	87.84	79.40
Operating Profit	14.41	20.37	21.34	15.27	10.48	21.74	12.41	8.05	9.29	29.18	17.13	5.97	-7.70
OPM %	18.06%	21.57%	23.45%	17.20%	13.08%	22.49%	11.84%	9.76%	9.50%	23.73%	14.64%	6.36%	-10.74%
Other Income	4.25	6.45	6.22	7.13	5.32	6.29	6.66	5.94	4.67	6.93	5.56	1.02	1.55
Interest	1.93	2.26	2.37	2.23	2.71	2.49	2.04	2.68	2.16	2.36	2.44	2.79	2.45
Depreciation	2.39	2.46	2.56	2.67	2.80	3.03	3.07	3.10	3.06	2.41	2.45	2.54	2.53
Profit before tax	14.34	22.10	22.63	17.50	10.29	22.51	13.96	8.21	8.74	31.34	17.80	1.66	-11.13
Tax %	30.61%	21.22%	21.43%	23.94%	18.37%	19.19%	18.91%	10.35%	24.14%	21.25%	19.66%	68.67%	-13.12%
Net Profit	9.95	17.40	17.78	13.31	8.41	18.19	11.32	7.37	6.64	24.68	14.29	0.52	-9.66
EPS in Rs	1.08	1.89	1.93	1.45	0.91	1.98	1.23	0.80	0.72	2.68	1.55	0.06	-1.05

Last Updated: May 31, 2025, 7:31 am

Below is a detailed analysis of the quarterly data for Themis Medicare Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

For Sales, as of Mar 2025, the value is 71.70 Cr.. The value appears to be declining and may need further review. It has decreased from 93.81 Cr. (Dec 2024) to 71.70 Cr., marking a decrease of 22.11 Cr..
For Expenses, as of Mar 2025, the value is 79.40 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 87.84 Cr. (Dec 2024) to 79.40 Cr., marking a decrease of 8.44 Cr..
For Operating Profit, as of Mar 2025, the value is -7.70 Cr.. The value appears to be declining and may need further review. It has decreased from 5.97 Cr. (Dec 2024) to -7.70 Cr., marking a decrease of 13.67 Cr..
For OPM %, as of Mar 2025, the value is -10.74%. The value appears to be declining and may need further review. It has decreased from 6.36% (Dec 2024) to -10.74%, marking a decrease of 17.10%.
For Other Income, as of Mar 2025, the value is 1.55 Cr.. The value appears strong and on an upward trend. It has increased from 1.02 Cr. (Dec 2024) to 1.55 Cr., marking an increase of 0.53 Cr..
For Interest, as of Mar 2025, the value is 2.45 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 2.79 Cr. (Dec 2024) to 2.45 Cr., marking a decrease of 0.34 Cr..
For Depreciation, as of Mar 2025, the value is 2.53 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 2.54 Cr. (Dec 2024) to 2.53 Cr., marking a decrease of 0.01 Cr..
For Profit before tax, as of Mar 2025, the value is -11.13 Cr.. The value appears to be declining and may need further review. It has decreased from 1.66 Cr. (Dec 2024) to -11.13 Cr., marking a decrease of 12.79 Cr..
For Tax %, as of Mar 2025, the value is -13.12%. The value appears to be improving (decreasing) as expected. It has decreased from 68.67% (Dec 2024) to -13.12%, marking a decrease of 81.79%.
For Net Profit, as of Mar 2025, the value is -9.66 Cr.. The value appears to be declining and may need further review. It has decreased from 0.52 Cr. (Dec 2024) to -9.66 Cr., marking a decrease of 10.18 Cr..
For EPS in Rs, as of Mar 2025, the value is -1.05. The value appears to be declining and may need further review. It has decreased from 0.06 (Dec 2024) to -1.05, marking a decrease of 1.11.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: June 16, 2025, 3:43 pm

Metric	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Sales	195	202	232	217	210	184	202	231	395	354	382	406
Expenses	171	184	194	184	184	181	166	181	299	287	330	356
Operating Profit	24	18	38	33	25	2	36	49	96	67	52	49
OPM %	12%	9%	16%	15%	12%	1%	18%	21%	24%	19%	13%	12%
Other Income	5	13	3	4	6	5	12	13	18	25	24	11
Interest	16	15	12	12	12	12	13	13	9	10	9	10
Depreciation	9	11	12	7	7	8	8	9	9	10	12	10
Profit before tax	4	5	17	18	11	-13	27	41	95	73	53	40
Tax %	32%	-20%	11%	9%	1%	-15%	8%	14%	23%	22%	19%	25%
Net Profit	3	6	16	16	11	-11	25	36	73	57	44	30
EPS in Rs	0.32	0.73	1.91	1.77	1.23	-1.17	2.70	3.88	7.92	6.18	4.73	3.24
Dividend Payout %	28%	25%	9%	0%	0%	0%	6%	11%	6%	8%	11%	0%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year	2014-2015	2015-2016	2016-2017	2017-2018	2018-2019	2019-2020	2020-2021	2021-2022	2022-2023	2023-2024	2024-2025
YoY Net Profit Growth (%)	100.00%	166.67%	0.00%	-31.25%	-200.00%	327.27%	44.00%	102.78%	-21.92%	-22.81%	-31.82%
Change in YoY Net Profit Growth (%)	0.00%	66.67%	-166.67%	-31.25%	-168.75%	527.27%	-283.27%	58.78%	-124.70%	-0.89%	-9.01%

Themis Medicare Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:	7%
5 Years:	15%
3 Years:	1%
TTM:	6%

Compounded Profit Growth
10 Years:	17%
5 Years:	4%
3 Years:	-25%
TTM:	-29%

Stock Price CAGR
10 Years:	24%
5 Years:	30%
3 Years:	20%
1 Year:	-38%

Return on Equity
10 Years:	13%
5 Years:	15%
3 Years:	12%
Last Year:	8%

Last Updated: Unknown

Balance Sheet

Last Updated: June 16, 2025, 11:12 am

Month	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity Capital	8	8	9	9	9	9	9	9	9	9	9	9
Reserves	48	51	66	143	160	149	174	209	278	330	368	393
Borrowings	148	140	128	82	80	82	100	87	80	92	96	83
Other Liabilities	79	77	73	54	56	74	67	65	61	82	93	102
Total Liabilities	284	277	275	289	305	314	350	371	428	514	566	588
Fixed Assets	121	122	117	124	126	123	116	133	144	162	168	172
CWIP	12	4	6	9	2	2	8	2	3	3	3	3
Investments	4	5	6	23	24	27	35	45	56	70	89	95
Other Assets	147	146	146	133	153	162	191	191	225	279	307	318
Total Assets	284	277	275	289	305	314	350	371	428	514	566	588

Below is a detailed analysis of the balance sheet data for Themis Medicare Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

For Equity Capital, as of Mar 2025, the value is 9.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 9.00 Cr..
For Reserves, as of Mar 2025, the value is 393.00 Cr.. The value appears strong and on an upward trend. It has increased from 368.00 Cr. (Mar 2024) to 393.00 Cr., marking an increase of 25.00 Cr..
For Borrowings, as of Mar 2025, the value is 83.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 96.00 Cr. (Mar 2024) to 83.00 Cr., marking a decrease of 13.00 Cr..
For Other Liabilities, as of Mar 2025, the value is 102.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 93.00 Cr. (Mar 2024) to 102.00 Cr., marking an increase of 9.00 Cr..
For Total Liabilities, as of Mar 2025, the value is 588.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 566.00 Cr. (Mar 2024) to 588.00 Cr., marking an increase of 22.00 Cr..
For Fixed Assets, as of Mar 2025, the value is 172.00 Cr.. The value appears strong and on an upward trend. It has increased from 168.00 Cr. (Mar 2024) to 172.00 Cr., marking an increase of 4.00 Cr..
For CWIP, as of Mar 2025, the value is 3.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 3.00 Cr..
For Investments, as of Mar 2025, the value is 95.00 Cr.. The value appears strong and on an upward trend. It has increased from 89.00 Cr. (Mar 2024) to 95.00 Cr., marking an increase of 6.00 Cr..
For Other Assets, as of Mar 2025, the value is 318.00 Cr.. The value appears strong and on an upward trend. It has increased from 307.00 Cr. (Mar 2024) to 318.00 Cr., marking an increase of 11.00 Cr..
For Total Assets, as of Mar 2025, the value is 588.00 Cr.. The value appears strong and on an upward trend. It has increased from 566.00 Cr. (Mar 2024) to 588.00 Cr., marking an increase of 22.00 Cr..

Notably, the Reserves (393.00 Cr.) exceed the Borrowings (83.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Reserves and Borrowings Chart

Cash Flow

Month	Month		Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Cash from Operating Activity +	8	19	26	-2	8	11	0	57	34	16	22	35
Cash from Investing Activity +	-7	-6	-7	-4	-0	-4	-5	-16	-16	-24	-16	-12
Cash from Financing Activity +	2	-18	-13	5	-9	-10	7	-26	-18	0	-9	-26
Net Cash Flow	4	-5	5	-0	-1	-3	2	16	1	-8	-3	-3

Free Cash Flow

Month	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Free Cash Flow	-124.00	-122.00	-90.00	-49.00	-55.00	-80.00	-64.00	-38.00	16.00	-25.00	-44.00	-34.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Debtor Days	68	74	82	75	81	120	145	186	123	93	149	170
Inventory Days	246	280	246	243	250	253	287	315	272	150	213	188
Days Payable	232	240	237	145	163	156	187	171	143	79	123	126
Cash Conversion Cycle	82	114	91	172	168	216	244	330	251	164	239	232
Working Capital Days	87	81	78	64	74	131	132	176	152	124	176	180
ROCE %	5%	10%	9%	15%	13%	10%	-1%	15%	18%	30%	20%	14%

Financial Efficiency Indicators Chart

Share Holding Pattern

Month	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024
Promoters	67.18%	67.18%	67.17%	67.17%	67.16%	67.16%	67.16%	67.16%	67.15%	67.15%	67.15%	67.15%
FIIs	0.00%	0.00%	0.02%	0.02%	0.06%	0.04%	0.05%	0.01%	0.03%	0.05%	0.10%	0.10%
DIIs	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%
Public	32.81%	32.81%	32.80%	32.78%	32.78%	32.80%	32.77%	32.82%	32.81%	32.79%	32.74%	32.75%
No. of Shareholders	5,891	5,915	6,126	6,362	5,927	6,007	6,970	11,244	11,295	11,322	14,270	17,773

Shareholding Pattern Chart

No. of Shareholders

Mutual Fund Holdings

Fund Name	No of Shares	AUM (%)	Amount Invested (Cr)	Previous Number of Shares	Previous Date	Percentage Change
Motilal Oswal S&P BSE Healthcare ETF	322	0.08	0.01	322	2025-04-22 17:25:18	0%

ROCE Trend

EPS Trend

Key Financial Ratios

Month	Mar 25	Mar 24	Mar 23	Mar 22	Mar 21
FaceValue	1.00	1.00	10.00	10.00	10.00
Basic EPS (Rs.)	3.24	4.73	61.83	79.22	38.86
Diluted EPS (Rs.)	3.24	4.72	61.73	79.07	38.84
Cash EPS (Rs.)	3.68	4.02	58.44	77.19	37.85
Book Value[Excl.RevalReserv]/Share (Rs.)	43.74	41.03	368.85	312.48	237.80
Book Value[Incl.RevalReserv]/Share (Rs.)	43.74	41.03	368.85	312.48	237.80
Revenue From Operations / Share (Rs.)	44.06	41.48	385.02	428.91	251.04
PBDIT / Share (Rs.)	5.84	6.11	85.80	111.06	57.81
PBIT / Share (Rs.)	4.76	4.78	74.39	100.75	48.50
PBT / Share (Rs.)	3.67	3.76	64.00	91.22	34.67
Net Profit / Share (Rs.)	2.60	2.69	47.03	66.89	28.54
NP After MI And SOA / Share (Rs.)	3.24	4.73	61.83	79.22	38.86
PBDIT Margin (%)	13.24	14.73	22.28	25.89	23.02
PBIT Margin (%)	10.79	11.52	19.32	23.49	19.32
PBT Margin (%)	8.32	9.07	16.62	21.26	13.81
Net Profit Margin (%)	5.89	6.47	12.21	15.59	11.37
NP After MI And SOA Margin (%)	7.35	11.40	16.05	18.46	15.47
Return on Networth / Equity (%)	7.41	11.52	16.76	25.35	16.33
Return on Capital Employeed (%)	10.13	10.68	18.26	29.12	18.35
Return On Assets (%)	5.07	7.68	11.07	17.03	9.61
Long Term Debt / Equity (X)	0.04	0.07	0.08	0.08	0.10
Total Debt / Equity (X)	0.20	0.25	0.27	0.27	0.36
Asset Turnover Ratio (%)	0.70	0.70	0.75	1.05	0.67
Current Ratio (X)	1.95	1.90	1.90	1.96	1.45
Quick Ratio (X)	1.41	1.44	1.41	1.40	0.98
Inventory Turnover Ratio (X)	0.98	1.21	1.48	1.90	1.20
Dividend Payout Ratio (NP) (%)	0.00	10.57	8.08	5.42	4.50
Dividend Payout Ratio (CP) (%)	0.00	8.25	6.82	4.80	3.63
Earning Retention Ratio (%)	0.00	89.43	91.92	94.58	95.50
Cash Earning Retention Ratio (%)	0.00	91.75	93.18	95.20	96.37
Interest Coverage Ratio (X)	5.35	6.00	8.26	11.64	4.18
Interest Coverage Ratio (Post Tax) (X)	3.38	3.64	5.53	8.01	3.06
Enterprise Value (Cr.)	1419.92	2092.17	1146.53	910.58	312.04
EV / Net Operating Revenue (X)	3.50	5.48	3.24	2.31	1.35
EV / EBITDA (X)	26.43	37.19	14.52	8.91	5.87
MarketCap / Net Operating Revenue (X)	3.33	5.28	3.03	2.18	1.12
Retention Ratios (%)	0.00	89.42	91.91	94.57	95.49
Price / BV (X)	3.35	5.34	3.16	2.99	1.18
Price / Net Operating Revenue (X)	3.33	5.28	3.03	2.18	1.12
EarningsYield	0.02	0.02	0.05	0.08	0.13

After reviewing the key financial ratios for Themis Medicare Ltd, here is a detailed analysis based on the latest available data and recent trends:

For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
For Basic EPS (Rs.), as of Mar 25, the value is 3.24. This value is below the healthy minimum of 5. It has decreased from 4.73 (Mar 24) to 3.24, marking a decrease of 1.49.
For Diluted EPS (Rs.), as of Mar 25, the value is 3.24. This value is below the healthy minimum of 5. It has decreased from 4.72 (Mar 24) to 3.24, marking a decrease of 1.48.
For Cash EPS (Rs.), as of Mar 25, the value is 3.68. This value is within the healthy range. It has decreased from 4.02 (Mar 24) to 3.68, marking a decrease of 0.34.
For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 43.74. It has increased from 41.03 (Mar 24) to 43.74, marking an increase of 2.71.
For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 43.74. It has increased from 41.03 (Mar 24) to 43.74, marking an increase of 2.71.
For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 44.06. It has increased from 41.48 (Mar 24) to 44.06, marking an increase of 2.58.
For PBDIT / Share (Rs.), as of Mar 25, the value is 5.84. This value is within the healthy range. It has decreased from 6.11 (Mar 24) to 5.84, marking a decrease of 0.27.
For PBIT / Share (Rs.), as of Mar 25, the value is 4.76. This value is within the healthy range. It has decreased from 4.78 (Mar 24) to 4.76, marking a decrease of 0.02.
For PBT / Share (Rs.), as of Mar 25, the value is 3.67. This value is within the healthy range. It has decreased from 3.76 (Mar 24) to 3.67, marking a decrease of 0.09.
For Net Profit / Share (Rs.), as of Mar 25, the value is 2.60. This value is within the healthy range. It has decreased from 2.69 (Mar 24) to 2.60, marking a decrease of 0.09.
For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 3.24. This value is within the healthy range. It has decreased from 4.73 (Mar 24) to 3.24, marking a decrease of 1.49.
For PBDIT Margin (%), as of Mar 25, the value is 13.24. This value is within the healthy range. It has decreased from 14.73 (Mar 24) to 13.24, marking a decrease of 1.49.
For PBIT Margin (%), as of Mar 25, the value is 10.79. This value is within the healthy range. It has decreased from 11.52 (Mar 24) to 10.79, marking a decrease of 0.73.
For PBT Margin (%), as of Mar 25, the value is 8.32. This value is below the healthy minimum of 10. It has decreased from 9.07 (Mar 24) to 8.32, marking a decrease of 0.75.
For Net Profit Margin (%), as of Mar 25, the value is 5.89. This value is within the healthy range. It has decreased from 6.47 (Mar 24) to 5.89, marking a decrease of 0.58.
For NP After MI And SOA Margin (%), as of Mar 25, the value is 7.35. This value is below the healthy minimum of 8. It has decreased from 11.40 (Mar 24) to 7.35, marking a decrease of 4.05.
For Return on Networth / Equity (%), as of Mar 25, the value is 7.41. This value is below the healthy minimum of 15. It has decreased from 11.52 (Mar 24) to 7.41, marking a decrease of 4.11.
For Return on Capital Employeed (%), as of Mar 25, the value is 10.13. This value is within the healthy range. It has decreased from 10.68 (Mar 24) to 10.13, marking a decrease of 0.55.
For Return On Assets (%), as of Mar 25, the value is 5.07. This value is within the healthy range. It has decreased from 7.68 (Mar 24) to 5.07, marking a decrease of 2.61.
For Long Term Debt / Equity (X), as of Mar 25, the value is 0.04. This value is below the healthy minimum of 0.2. It has decreased from 0.07 (Mar 24) to 0.04, marking a decrease of 0.03.
For Total Debt / Equity (X), as of Mar 25, the value is 0.20. This value is within the healthy range. It has decreased from 0.25 (Mar 24) to 0.20, marking a decrease of 0.05.
For Asset Turnover Ratio (%), as of Mar 25, the value is 0.70. There is no change compared to the previous period (Mar 24) which recorded 0.70.
For Current Ratio (X), as of Mar 25, the value is 1.95. This value is within the healthy range. It has increased from 1.90 (Mar 24) to 1.95, marking an increase of 0.05.
For Quick Ratio (X), as of Mar 25, the value is 1.41. This value is within the healthy range. It has decreased from 1.44 (Mar 24) to 1.41, marking a decrease of 0.03.
For Inventory Turnover Ratio (X), as of Mar 25, the value is 0.98. This value is below the healthy minimum of 4. It has decreased from 1.21 (Mar 24) to 0.98, marking a decrease of 0.23.
For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 10.57 (Mar 24) to 0.00, marking a decrease of 10.57.
For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 8.25 (Mar 24) to 0.00, marking a decrease of 8.25.
For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 89.43 (Mar 24) to 0.00, marking a decrease of 89.43.
For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 91.75 (Mar 24) to 0.00, marking a decrease of 91.75.
For Interest Coverage Ratio (X), as of Mar 25, the value is 5.35. This value is within the healthy range. It has decreased from 6.00 (Mar 24) to 5.35, marking a decrease of 0.65.
For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 3.38. This value is within the healthy range. It has decreased from 3.64 (Mar 24) to 3.38, marking a decrease of 0.26.
For Enterprise Value (Cr.), as of Mar 25, the value is 1,419.92. It has decreased from 2,092.17 (Mar 24) to 1,419.92, marking a decrease of 672.25.
For EV / Net Operating Revenue (X), as of Mar 25, the value is 3.50. This value exceeds the healthy maximum of 3. It has decreased from 5.48 (Mar 24) to 3.50, marking a decrease of 1.98.
For EV / EBITDA (X), as of Mar 25, the value is 26.43. This value exceeds the healthy maximum of 15. It has decreased from 37.19 (Mar 24) to 26.43, marking a decrease of 10.76.
For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 3.33. This value exceeds the healthy maximum of 3. It has decreased from 5.28 (Mar 24) to 3.33, marking a decrease of 1.95.
For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. It has decreased from 89.42 (Mar 24) to 0.00, marking a decrease of 89.42.
For Price / BV (X), as of Mar 25, the value is 3.35. This value exceeds the healthy maximum of 3. It has decreased from 5.34 (Mar 24) to 3.35, marking a decrease of 1.99.
For Price / Net Operating Revenue (X), as of Mar 25, the value is 3.33. This value exceeds the healthy maximum of 3. It has decreased from 5.28 (Mar 24) to 3.33, marking a decrease of 1.95.
For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.02.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Themis Medicare Ltd as of June 30, 2025 is: 109.53

Calculation basis:

Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of June 30, 2025, Themis Medicare Ltd is Overvalued by 17.02% compared to the current share price 132.00

Intrinsic Value of Themis Medicare Ltd as of June 30, 2025 is: 105.65

Calculation basis:

Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of June 30, 2025, Themis Medicare Ltd is Overvalued by 19.96% compared to the current share price 132.00

Last 5 Year EPS CAGR: -3.54%

*Investments are subject to market risks

Strength and Weakness

Strength	Weakness
The company has higher reserves (197.42 cr) compared to borrowings (99.83 cr), indicating strong financial stability. The company has shown consistent growth in sales (267.50 cr) and profit (30.92 cr) over the years.	The stock has a low average ROCE of 13.17%, which may not be favorable. The stock has a high average Working Capital Days of 121.25, which may not be favorable. The stock has a high average Cash Conversion Cycle of 191.92, which may not be favorable.

Stock Analysis

Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Themis Medicare Ltd:
1. Net Profit Margin: 5.89%
  - Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
2. ROCE: 10.13% (Industry Average ROCE: 16.64%)
  - ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
3. ROE%: 7.41% (Industry Average ROE: 15.19%)
  - ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
4. Interest Coverage Ratio (Post Tax): 3.38
  - Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
5. Quick Ratio: 1.41
  - Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
6. Stock P/E: 40.8 (Industry average Stock P/E: 101.91)
  - Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
7. Total Debt / Equity: 0.2
  - Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
Stock Rating:

About the Company - Qualitative Analysis

Themis Medicare Ltd. is a Public Limited Listed company incorporated on 31/05/1969 and has its registered office in the State of Gujarat, India. Company's Corporate Identification Number(CIN) is L24110GJ1969PLC001590 and registration number is 001590. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company's Total Operating Revenue is Rs. 405.51 Cr. and Equity Capital is Rs. 9.20 Cr. for the Year ended 31/03/2025.

INDUSTRY	ADDRESS	CONTACT
Pharmaceuticals	Plot No.69-A, GIDC Industrial Estate, Valsad District Gujarat 396195	themis@themismedicare.com http://www.themismedicare.com

Management
Name	Position Held
Dr. Dinesh S Patel	Chairman & Executive Director
Dr. Sachin D Patel	Managing Director & CEO
Mr. Rajneesh Anand	Non Executive Director
Dr. Adam Demeter	Non Executive Director
Mr. Hariharan Subramaniam	Independent Director
Ms. Manjul Sandhu	Independent Director
Mr. Bhaskar V Iyer	Independent Director
Mr. Shishir Dalal	Independent Director
Mrs. Reena S Patel	Alternate Director

FAQ

What is the intrinsic value of Themis Medicare Ltd?

Themis Medicare Ltd's intrinsic value (as of 30 June 2025) is 109.53 — 17.02% lower the current market price of 132.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 1,216 Cr. market cap, FY2025-2026 high/low of 317/115, reserves of 393 Cr, and liabilities of 588 Cr.

What is the Market Cap of Themis Medicare Ltd?

The Market Cap of Themis Medicare Ltd is 1,216 Cr..

What is the current Stock Price of Themis Medicare Ltd as on 30 June 2025?

The current stock price of Themis Medicare Ltd as on 30 June 2025 is 132.

What is the High / Low of Themis Medicare Ltd stocks in FY 2025-2026?

In FY 2025-2026, the High / Low of Themis Medicare Ltd stocks is ₹317/115.

What is the Stock P/E of Themis Medicare Ltd?

The Stock P/E of Themis Medicare Ltd is 40.8.

What is the Book Value of Themis Medicare Ltd?

The Book Value of Themis Medicare Ltd is 43.7.

What is the Dividend Yield of Themis Medicare Ltd?

The Dividend Yield of Themis Medicare Ltd is 0.38 %.

What is the ROCE of Themis Medicare Ltd?

The ROCE of Themis Medicare Ltd is 10.4 %.

What is the ROE of Themis Medicare Ltd?

The ROE of Themis Medicare Ltd is 7.65 %.

What is the Face Value of Themis Medicare Ltd?

The Face Value of Themis Medicare Ltd is 1.00.